ArticleScientific reports2025
E2F1-mediated PKMYT1 upregulation promotes prostate cancer progression by inhibiting the PPAR signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context-Dependent Therapeutic Vulnerability.Genes, chromosomes & cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein kinase membrane associated tyrosine/threonine 1 (PKMYT1) is a protein-coding gene associated with cell cycle regulation and cancer development, but its specific mechanism in prostate cancer (PCa) has not been clarified. This study sought to elucidate the role of PKMYT1 in PCa. Expression patterns, prognostic significance and potential mechanisms of PKMYT1 were explored by the TCGA database. Single-cell sequencing was performed using the GSE137829 dataset. Multi-database prediction identified potential transcription factors regulating PKMYT1 expression. PC3 cell line with PKMYT1 knockdown was established. Functional analyses (CCK-8, Wound healing, and Transwell assays) were performed to investigate the changes in tumor malignant behavior after PKMYT1 silencing. Western blot experiments were performed to analyze the effects of PKMYT1 on epithelial-mesenchymal transition (EMT) and PPAR signaling pathway. PKMYT1 was overexpressed in prostate cancer samples and its high expression was significantly associated with poor prognosis and Th2 cell infiltration. Knockdown of PKMYT1 could effectively inhibit the proliferation, migration, and EMT process of PCa cells. Mechanistically, E2F1 is an important factor regulating PKMYT1 expression, and PKMYT1 could inhibit the activity of the PPAR signaling pathway, thus ensuring the reinforcement of PCa progression. PKMYT1 can accelerate the progression of PCa by regulating the cell cycle, EMT process and PPAR signaling pathway. Targeting PKMYT1 provide a new perspective for the treatment of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.